Member Info for TorquayFan

Scancell advised the US Library of Medicine, Bazooka's source, on June 2nd.
When's our turn then ?

Just a hunch - an RNS today giving an update on the format of the Covidity trial ?
As notified by Bazooka last Thursday . . . . . .

That's a great find Cleaner. It would have been surprising if CEPI had been fooled into any sort of complacency during the current lull in the activity of the virus. I don't suppose the CEPI writer is thinking of Scancell when this was written, but who knows ?

"Multiple safe and effective COVID-19 vaccines are now globally available. But there is still substantial scope to optimize and improve the design and use of these vaccines to maximize their global health impact and their impact in different at-risk populations (such as elderly populations or in people who are immunocompromised) who may respond in different ways to a vaccine. We can make it easier to deploy vaccines through regimens of single-dose instead of multiple-dose vaccines, especially in countries with transient populations or weaker health systems, or in high-risk environments such as refugee camps. And developing vaccines that don’t require challenging cold-chain requirements would help in low-resource settings that lack this infrastructure."

Good to see Cleaner, thanks.

Thanks Baz.

WTP - "Participants enrolled under protocol Amendment 2: Vaccine Naive and Previously Vaccinated participants: Two doses of SCOV2 (administered on Day 1 and Day 29) with a final end of study assessment performed 6 weeks after last dose of study vaccine (Day 71); Previously Infected participants: A single dose of SCOV2 (administered on Day 1) with a final end of study assessment performed 6 weeks after last dose of study vaccine (Day 43)

Each dose of SCOV1 and/or SCOV2 will be administered via needle-free injection, either intradermally (study Arm 1; PharmaJet Tropis® device) or intramuscularly (study Arm 2; PharmaJet Stratis® device). Eligible injection sites include the outer aspect of the upper left or right arm (medial deltoid muscle) or the left or right outer thigh (lateralis muscle).

This study is expected to enrol up to 80 participants at a single centre in South Africa. Enrolment will attempt to continue until at least 10 evaluable participants receive all protocol-required SCOV2 vaccinations for each immunogenicity analysis population. However, should the epidemiology be such that certain populations cannot be enrolled, the Safety Review Committee may determine that enrolment for that population be considered complete."

Some changes there ?

Ruck post rec. Are you quite well ? ATB

Ruck - you ask 'why the interest?' - that really is dismissive. The new Patent is important and of interest ! Hopefully one day the scientific papers will be shown to have been the precursor for commercial returns.

You really are a grump these days . . . .

Some great posts today and thanks to those explaining matters.

Thanks Ruck - it's hard to believe I know, but the Writer didn't actually have you in mind . . .
But re. retirement plans, you are not alone ! ATB

Plenty of scope for a vaccine giving wider ranging and longer lasting immunity . . . . . . . . . . Covidity please.

An "important factor at play is the dramatic shift in testing habits. Since April, most people have had to pay for Covid tests, meaning far fewer infections are being confirmed and logged as cases. Whereas lateral flow and PCR tests in the community once detected perhaps half of all Covid infections, they are now picking up less than one in 10, according to Paul Hunter, professor of medicine at the University of East Anglia. “The daily dashboard isn’t picking up anywhere near as many infections as it was,” he said. According to the government’s Covid dashboard, daily cases in England have fallen by 98% since the start of the year. They now sit below 5,000 cases a day for the first time since last June . . . . In contrast, the Office for National Statistics, which estimates infection levels from swabs taken in random homes around the country, has recorded only a 73% fall in prevalence in England". . .

.. . . "With the full relaxation of Covid rules, the steady filling of offices, and people gradually reverting to pre-pandemic behaviour, there is plenty of scope for the virus to spread. And as immunity wanes from vaccinations and past infections, protection against infection will be the first line of defence to fail. In contrast, the Office for National Statistics, which estimates infection levels from swabs taken in random homes around the country, has recorded only a 73% fall in prevalence in England, from more than 3 million people infected in the week ending 31 December to nearly 875,000 in the week ending 21 May." . . .

. . . . "The UK Health Security Agency declared BA.4 and BA.5 “variants of concern” last week, as new data revealed they had a growth advantage over BA.2. Another descendant causing concern is BA.2.12.1, which spreads faster still . . . "

https://www.theguardian.com/world/2022/may/31/as-uk-covid-cases-fall-to-lowest-level-for-a-year-what-could-the-future-look-like

Some think it's all over - not yet ! Come on Scancell !

Thanks Crumbs - it's been a while ?

"The proposed acquisition further strengthens our vaccines R&D pipeline, provides access to a new, potentially disruptive technology, and broadens GSK's existing scientific footprint in the Boston area,” said Dr Hal Barron, GSK’s chief scientific officer."

So can Scancell's platforms be described as 'potentially disruptive technology' ??

I think so . . . .

Thanks Bermuda re. 'wording', I'm just checking that you saw Johnny's 11.51 yesterday? If Inan's idea is right that would be great but I take the point that there could be other explanations.

(It's confusing that the Covidity discussion has been on the Lindy thread about Modi 1).

Repeat of 07.57, Inan 50758 - "receive 1 or 2 dose ....... looks like they are getting a big enough response from 1 dose to be able to look more closely at the 1 dose only route ..... leaving enough room in the advert for the second dose if a % don't mount a sufficient response so can receive 2 . Obviously if approved they need min % to mount a response of sufficient magnitude with 1 dose as it would be impossible to test for those that only require 1 shot, so you can see that the data coming from the trial may indicate that 1 shot is sufficient ... But gives us a massive "hint" that it works -so this is the first signal that Covid vaccine works and may be better than expected ..."

I wonder if Posters here agree with Inan's thoughts ?

Douve I agree the news of the 'Ready 4' wouldn't warrant an RNS but IMO it is nevertheless very good to know. Hopefully an FPD will not be too far away. It looks as if there is some progress being made despite all.

Ruck I agree with you and Konar too but that's the way it is with Scancell.

'Leaked emails' - why do you suggest that ? Isn't 'shared' a better word ?

'Massive speculation' ? Bobbust's post simply quotes about Modi 1 - "Trials are progressing. Modi1 has four ready to go".

Hello Douve. To be fair, wasn't this new ?
"Modi1 has four ready to go.They just need a short break from previous treatments before they start."

Re. your comment, "I live in hope as always for left field news or a surprise deal". Me too !!! ATB

Yes AB - I did see it. I attributed Bobbust over there.
Bobbust thanks for alleviating the lack of news flow.
Great news.

Inan 50759 just now - "Modi1 ........ 4 ready - that is sufficient number to complete the first part of the safety run trial"

Inan 50758 just now - "receive 1 or 2 dose .......

looks like they are getting a big enough response from 1 dose to be able to look more closely at the 1 dose only route .....

leaving enough room in the advert for the second dose if a % don't mount a sufficient response so can receive 2 . Obviously if approved they need min % to mount a response of sufficient magnitude with 1 dose as it would be impossible to test for those that only require 1 shot, so you can see that the data coming from the trial may indicate that 1 shot is sufficient ... But gives us a massive "hint" that it works

so this is the first signal that Covid vaccine works and may be better than expected ..."

Thanks inan

C11 a great spot. Thanks to Johnny for his insights which are thankfully positive ! I guess it's 'wait and see' again.

C11 - I recently isolated for 9 days but the symptoms were very mild - just tiredness, (last year it was very unpleasant).
'Far from over' - indeed so. Take care and GWS !

Blockbuster !

Tick tock . . . . . . . . . . .